secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0001493152-23-023439
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Eton terminates stalking horse bid for Vistogard, Xuriden; receives $800K break-up fee
--------------------------------------------------------------------------------

- Terminated Asset Purchase Agreement with Wellstat Debtors after losing bankruptcy auction on June 30, 2023.
- Stalking horse bidder for Vistogard and Xuriden; consideration was $34M–$37M.
- Received $800,000 break-up fee plus reimbursement of third-party expenses.
- Eton was not the successful bidder; no assets were acquired.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223023439/0001493152-23-023439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223023439/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-023439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer